⚡ INSURANCE COVERAGE AUDIT: October 8, 2026 • 45M Americans Excluded from GLP-1s • Direct 503A Access Open
⚡ ⚡ 2026 Insurance Exclusion Audit

Denied GLP-1 Coverage? Calculate Your 503A Direct-Access Savings

Take this free 60-second coverage assessment to calculate your monthly savings bypassing commercial insurance denials, and see if you qualify for state-licensed 503A compounded Semaglutide for a flat $79/mo.

⚠️ ACCESS ALERT: COMMERCIAL DENIAL ALERT: Over 85% of employer healthcare policies and Medicare now strictly exclude GLP-1 medications for weight management, leaving patients facing $1,350/mo pharmacy bills.
✓
Instant 60-Second Denial Bypass: Zero prior authorizations, appeal letters, or insurance rejections.
✓
Direct 503A Pharmacy Savings: Unlock flat $79/mo compounded Semaglutide—saving up to $1,071/mo off retail prices.
✓
Licensed US Cleanrooms: Prepared in certified sterile 503A pharmacies adhering to USP <797> standards.
🟢 35,120 Coverage Audits Completed This Month • $0 Prior Auth Delay
⚡ Question 1 of 10
10% Complete

What was the primary reason provided for your GLP-1 prescription insurance denial?

Helps classify your health plan's restriction mechanism: